Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

otocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.

About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... A new research platform uses a laser ... structures undergoing stress and heating, an approach ... for microelectronics and batteries., This new technique, ... how heating and the surface stress of ... have discussed the merits of surface-stress influence ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... ... line of Spectrum benchtop laboratory equipment that is now available for the budget-conscious researcher ... baths, mini centrifuges, hotplates & magnetic stirrers for general sample preparation and laboratory mixing ... Gardena, ...
... ... general release , ... Charlottesville, VA, San Francisco, CA, New York, NY and Paris, France (PRWEB) January 8, ... software solution for managing and reporting aggregate spend. The company will be officially launching ...
... , , HAYWARD, Calif., Jan. 8 ... that it has obtained commitments from accredited institutional investors ... and warrants in a private placement. The financing was ... Great Point Partners along with participation from other existing ...
Cached Biology Technology:Spectrum Introduces New Line of Spectrum Branded Benchtop Laboratory Equipment 2OpenQ Announces openSpend for Physician Payment Sunshine Act Compliance 2Solta Medical to Raise $17.2 Million in Private Placement 2Solta Medical to Raise $17.2 Million in Private Placement 3Solta Medical to Raise $17.2 Million in Private Placement 4Solta Medical to Raise $17.2 Million in Private Placement 5
(Date:8/28/2014)... Research Careers) Program has announced the travel award recipients ... 18 22, 2014 in San Diego, California. ... students, post doctorates and scientists from underrepresented groups into ... encourage the participation of young scientists at the American ... 16 awards totaling $29,600., The FASEB MARC Program is ...
(Date:8/28/2014)... developmental on-off switch for Streptomyces , a group ... the world,s naturally derived antibiotic medicines. , Their ... possible to manipulate this switch to make nature,s antibiotic ... 28 in Cell , found that a unique ... larger protein called BldD ultimately controls whether a bacterium ...
(Date:8/28/2014)... method for measuring and imaging how quickly blood flows ... understand how drug abuse affects the brain, which may ... lead to better treatment options for recovering drug addicts. ... from Stony Brook University in New York, USA and ... in The Optical Society,s (OSA) open-access journal ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... flying in chevron formation or cyclists learned the value of ... their spores so as to spread them as high and ... Sclerotinia sclerotiorum , spews thousands of spores nearly simultaneously to ... even creates a wind that carries many of the spores ...
... to clean water and environmental causes, his dedication as ... the pursuit of discovery, Professor Xiaoguang Meng received an ... Technology at the university,s annual Convocation Ceremony on September ... Charles V. Schaefer, Jr. School of Engineering and Science, ...
... is now open to the press for the ... of America (ESA) and National Education Association, with ... October 14-15, 2010 in Washington, D.C. The summit ... educators, scientists, and policy professionals from a wide ...
Cached Biology News:Fungal spores travel farther by surfing their own wind 2Fungal spores travel farther by surfing their own wind 3Fungal spores travel farther by surfing their own wind 4Prof. Xiaoguang Meng receives honorary master of engineering from Stevens 2Prof. Xiaoguang Meng receives honorary master of engineering from Stevens 3Ecology and Education Summit to address environmental literacy 2
... units/µL ,• High specific activity and processivity ... 'A' overhang ,• Processes ... high activity in primer extension and other ... of the enzyme, each lot has been ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... high activity in primer extension and other ... of the enzyme, each lot has been ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Biology Products: